Stoke Therapeutics Profit Margin

Stoke Therapeutics posts a profit margin of -753.6% as of June 2026. That compares with 26.26% in the prior-year period — down 2970.2% year over year. That is below the Healthcare sector average of 21.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Stoke Therapeutics's profit margin was 26.26%. The latest reading is -753.6% — a 2970.2% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 21.34% is typical. Stoke Therapeutics's -753.6% is lower that level. That is roughly 3632.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Stoke Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -753.6% as of June 2026; use YoY and peer views to separate noise from signal.

Context for STOK's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.34%), and (3) consistency with growth and profitability. This page covers the first two; Stoke Therapeutics's other metric pages and overview cover the third.